425392-44-5

Basic information

• Product Name: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE
• Synonyms: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE;2-Bromo-5-chloro-1,3-thiazol-4-carboxylic ethyl ester;Ethyl 2-bromo-5-chloro-1,3-thiazole-4-carboxylate;2-Bromo-5-chloro-4-(ethoxycarbonyl)-1,3-thiazole;2-Bromo-5-chloro-4-thiazolecarboxylic acid ethyl ester;2-(1-(4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazine-1-carbonyl)cyclobutyl)acetic acid;2-Bromo-5-chloro-thiazole-4-carboxylic acid ethyl ester
• CAS NO: 425392-44-5
• Molecular Formula: C₆H₅BrClNO₂S
• Molecular Weight: 270.5314
• Product Categories: Building Blocks;Thiazole
• Mol File: 425392-44-5.mol

Chemical Properties

• Boiling Point: 313℃
• Flash Point: 143℃
• Appearance: /
• Density: 1.749
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.22±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(425392-44-5)
• EPA Substance Registry System: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(425392-44-5)

Safety Data

• Hazardous Substances Data: 425392-44-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE is used as a building block for the synthesis of pharmaceutical products due to its chemical structure and properties that make it suitable for the development of new drugs and medications.
Used in Academic and Research Settings:
In the realm of academia and research, ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE is utilized for the study of thiazole derivatives. This research is aimed at exploring their potential applications in drug development and other related fields, further expanding the horizons of pharmaceutical innovation.

Upstream product

• 136539-01-0 ethyl 2-amino-5-chloro-4-thiazole carboxylate 
• 5398-36-7 2-aminothiazole-4-carboxylate 

Downstream Products

• 425392-48-9 5-chloro-2-(4-methoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester 
• 425392-47-8 5-chloro-2-(2-methoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester 
• 425392-51-4 5-chloro-2-phenylethynyl-thiazole-4-carboxylic acid ethyl ester 
• 59937-01-8 2-phenylthiazole-4-carboxylic acid ethyl ester 
• 425392-45-6 5-chlorothiazole-4-carboxylic acid ethyl ester 
• 425392-46-7 5-chloro-2-phenylthiazole-4-carboxylic acid ethyl ester 
• 1027169-53-4 2-bromo-5-chlorothiazole-4-carboxylic acid 

Relevant articles and documents

Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2

Protein–protein interactions (PPIs), many of which are dominated by α-helical recognition domains, play key roles in many essential cellular processes, and the dysregulation of these interactions can cause detrimental effects. For instance, aberrant PPIs involving the Bcl-2 protein family can lead to several diseases including cancer, neurodegenerative diseases, and diabetes. Interactions between Bcl-2 pro-life proteins, such as Mcl-1, and pro-death proteins, such as Bim, regulate the intrinsic pathway of apoptosis. p53, a tumor-suppressor protein, also has a pivotal role in apoptosis and is negatively regulated by its E3 ubiquitin ligase HDM2. Both Mcl-1 and HDM2 are upregulated in numerous cancers, and, interestingly, there is crosstalk between both protein pathways. Recently, synergy has been observed between Mcl-1 and HDM2 inhibitors. Towards the development of new anticancer drugs, we herein describe a polypharmacology approach for the dual inhibition of Mcl-1 and HDM2 by employing three densely functionalized isoxazoles, pyrazoles, and thiazoles as mimetics of key α-helical domains of their partner proteins.

DUAL INHIBITORS OF THE BCL-2 AND HDM2 FAMILIES THROUGH CO-MIMICRY OF THE BH3 AND P53-ALPHA-HELICES

The invention relates to dual HDM2/Bcl-2 inhibitors, providing a synergistic effect to help promote apoptosis in tumorigenic cells.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of formula (I), wherein Q, A1-A8, R4 and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The present invention relates to thiazole derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cere

Synthesis of 2-aryl-oxazolo[4,5-c]quinoline-4(5H)-ones and 2-aryl-thiazolo[4,5-c]quinoline-4(5H)-ones

(Matrix presented) Novel and highly efficient syntheses of oxazolo[4,5-c]quinoline-4(5H)-ones (1) and thiazolo[4,5-c]quinoline-4(5H)-ones (2) from ethyl 2-chlorooxazole-4-carboxylate (4) and ethyl 2-bromo-5-chlorothiazole-4-carboxylate (13), respectively,

Synthesis of 2,5-dihalothiazole-4-carboxylates

An efficient synthesis of 2,5-dihalothiazole-4-carboxylates has been described. Halogenation of aminothiazole carboxylate with NBS or NCS and subsequent diazotization with isoamyl nitrite and halogenation with CuBr2, CuCl2 or CH2I2 provided the corresponding diahalothiazole derivatives. The four-step process described is amenable to scale-up and requires no chromatographic purification in all the steps.

Regiocontrolled Synthesis of Substituted Thiazoles

(Formula Presented) The regiocontrolled synthesis of 2,5-disubstituted and 2,4,5-trisubstituted thiazoles from ethyl 2-bromo-5-chloro-4-thiazolecarboxylate 1 using sequential palladium-catalyzed coupling reactions is described.